Stock listing
Frankfurt:CHY ChemoMetec A/S Aktie
German listing (Frankfurt) of ChemoMetec A/S · home listing Copenhagen:CHEMM
Follow ChemoMetec A/S into a list and get an email when it puts out news.
Share price · FWB:CHY
€89.65 EUR -3.00 (-3.2%)
Close on Nov 20, 2026
- Day range
- €89.65 – €92.30 EURNov 20, 2026
- Market cap
- €1.54B EURAt the close on Nov 20, 2026 · price × 17.16M shares outstanding
- 52-week range
- €33.66 – €106.52 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €1,687 EURMedian day 0 shares · 36 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Copenhagen:CHEMM · Home | 682.00 DKK | -12.50 (-1.8%) | 45,436 | 695.00 | 698.00 | 680.50 | 694.50 | Close on Nov 20, 2026 |
| Frankfurt:CHY | €89.65 EUR | -3.00 (-3.2%) | — | €91.50 | €92.30 | €89.65 | €92.65 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:CHY · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €93.53 | +4.22 | +4.7% | €87.93 | €94.30 | €87.86 | 0 | |
| €89.31 | +2.759 | +3.2% | €85.90 | €89.50 | €85.86 | 32 | |
| €86.55 | +5.195 | +6.4% | €86.72 | €87.01 | €86.23 | 2 | |
| €81.36 | -0.95 | -1.2% | €81.36 | €81.36 | €81.36 | 0 | |
| €82.31 | +1.163 | +1.4% | €81.09 | €82.73 | €80.85 | 0 | |
| €81.14 | -0.42 | -0.5% | €82.31 | €82.65 | €80.94 | 18 | |
| €81.56 | -0.902 | -1.1% | €81.55 | €81.65 | €80.81 | 80 | |
| €82.47 | +1.46 | +1.8% | €80.96 | €83.06 | €80.40 | 12 | |
| €81.01 | +1.204 | +1.5% | €81.01 | €81.01 | €81.01 | 0 | |
| €79.80 | +0.937 | +1.2% | €79.44 | €79.83 | €79.29 | 80 | |
| €78.86 | +0.306 | +0.4% | €78.86 | €78.86 | €78.86 | 120 | |
| €78.56 | -0.814 | -1.0% | €78.56 | €78.56 | €78.56 | 0 | |
| €79.37 | +3.484 | +4.6% | €76.70 | €79.59 | €75.66 | 4 | |
| €75.89 | +0.739 | +1.0% | €75.15 | €76.42 | €74.45 | 0 | |
| €75.15 | -1.738 | -2.3% | €75.15 | €75.15 | €75.15 | 0 | |
| €76.89 | +0.353 | +0.5% | €76.89 | €76.89 | €76.89 | 0 | |
| €76.53 | +1.455 | +1.9% | €76.53 | €76.53 | €76.53 | 0 | |
| €75.08 | -2.247 | -2.9% | €75.08 | €75.08 | €75.08 | 0 | |
| €77.33 | -1.004 | -1.3% | €77.43 | €77.43 | €77.19 | 0 | |
| €78.33 | +1.152 | +1.5% | €78.33 | €78.33 | €78.33 | 0 | |
| €77.18 | +1.367 | +1.8% | €74.40 | €77.42 | €73.64 | 112 | |
| €75.81 | +0.30 | +0.4% | €75.81 | €75.99 | €74.98 | 16 | |
| €75.51 | -2.544 | -3.3% | €76.43 | €77.92 | €74.92 | 5 | |
| €78.06 | +5.855 | +8.1% | €78.06 | €78.06 | €78.06 | 0 | |
| €72.20 | -0.712 | -1.0% | €72.20 | €72.20 | €72.20 | 0 | |
| €72.91 | +3.786 | +5.5% | €69.58 | €73.18 | €69.53 | 28 | |
| €69.13 | -0.371 | -0.5% | €69.78 | €70.04 | €68.50 | 0 | |
| €69.50 | +0.619 | +0.9% | €69.50 | €69.50 | €69.50 | 0 | |
| €68.88 | +0.294 | +0.4% | €68.88 | €68.88 | €68.88 | 0 | |
| €68.58 | -0.872 | -1.3% | €68.43 | €68.62 | €68.12 | 0 | |
| €69.46 | +1.12 | +1.6% | €69.85 | €70.26 | €69.32 | 22 | |
| €68.34 | -0.214 | -0.3% | €68.34 | €68.34 | €68.34 | 0 | |
| €68.55 | -0.038 | -0.1% | €68.84 | €69.71 | €68.55 | 0 | |
| €68.59 | +0.29 | +0.4% | €69.25 | €69.43 | €68.18 | 0 | |
| €68.30 | -0.565 | -0.8% | €68.30 | €68.30 | €68.30 | 0 | |
| €68.86 | +2.577 | +3.9% | €68.86 | €68.86 | €68.86 | 0 | |
| €66.29 | -0.034 | -0.1% | €66.29 | €66.29 | €66.29 | 0 | |
| €66.32 | +0.378 | +0.6% | €65.10 | €67.09 | €64.96 | 2 | |
| €65.94 | +1.492 | +2.3% | €64.37 | €65.97 | €63.99 | 200 | |
| €64.45 | -0.836 | -1.3% | €64.78 | €64.93 | €63.77 | 10 | |
| €65.29 | -2.218 | -3.3% | €66.67 | €67.11 | €64.49 | 10 | |
| €67.50 | -0.259 | -0.4% | €68.09 | €68.13 | €67.28 | 200 | |
| €67.76 | -0.258 | -0.4% | €67.83 | €67.84 | €67.74 | 0 | |
| €68.02 | +0.46 | +0.7% | €68.02 | €68.02 | €68.02 | 0 | |
| €67.56 | -1.272 | -1.8% | €67.56 | €67.56 | €67.56 | 0 | |
| €68.83 | +4.695 | +7.3% | €68.83 | €68.83 | €68.83 | 6 | |
| €64.14 | +1.797 | +2.9% | €64.14 | €64.14 | €64.14 | 0 | |
| €62.34 | -3.601 | -5.5% | €62.34 | €62.34 | €62.34 | 0 | |
| €65.94 | -1.321 | -2.0% | €65.94 | €65.94 | €65.94 | 0 | |
| €67.26 | +0.669 | +1.0% | €67.26 | €67.26 | €67.26 | 0 | |
| €66.59 | +1.789 | +2.8% | €66.59 | €66.59 | €66.59 | 6 | |
| €64.81 | -0.838 | -1.3% | €64.81 | €64.81 | €64.81 | 0 | |
| €65.64 | +0.837 | +1.3% | €65.64 | €65.64 | €65.64 | 0 | |
| €64.81 | +2.35 | +3.8% | €64.81 | €64.81 | €64.81 | 0 | |
| €62.46 | -0.674 | -1.1% | €62.46 | €62.46 | €62.46 | 0 | |
| €63.13 | -1.095 | -1.7% | €63.13 | €63.13 | €63.13 | 400 | |
| €64.23 | +1.75 | +2.8% | €64.23 | €64.23 | €64.23 | 0 |
- Ticker
- Frankfurt:CHY
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Sep 10, 2026
Guidance for the 2026/27 financial year
Latest news
Guidance for the 2026/27 financial year
Sep 10, 2026
Closed €65.29 (-3.3%) on Sep 11, 2026
ChemoMetec enters collaboration agreement with Roche Diagnostics
Aug 10, 2026
Closed €56.65 (+4.0%) on Aug 10, 2026
ChemoMetec A/S invites to conference call on September 11, 2026 at 3: 00 p.m. CEST on its upcoming 2025/26 Annual Report
Aug 7, 2026
Closed €54.50 (-0.4%) on Aug 7, 2026
Initiation of buy-back programme
May 15, 2026
Closed €42.18 (-2.3%) on May 15, 2026
Adjustment of accounting estimates contributes to an upgrade of revenue and operating profit guidance
May 4, 2026
Closed €43.27 (+4.3%) on May 4, 2026
Notification of managers’ transactions
Mar 27, 2026
Closed €39.28 (+7.5%) on Mar 27, 2026
Adjustment of guidance for 2025/26
Mar 24, 2026
Closed €37.91 (-27.3%) on Mar 25, 2026
Notification of managers' transactions
Mar 2, 2026
Closed €54.39 (-0.9%) on Mar 2, 2026
ChemoMetec enters Letter of Intent with Roche Diagnostics
Feb 4, 2026
Closed €61.69 (-24.2%) on Feb 5, 2026
Interim report 2025/26 - Organic growth despite challenges in the North American market
Feb 4, 2026
Closed €61.69 (-24.2%) on Feb 5, 2026
ChemoMetec A/S on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 10 in the last 12 months · 19 in all · newest Sep 10, 2026 · oldest 2025
- Decks
- 1 deck · latest Feb 6, 2024
Where ChemoMetec A/S is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Copenhagen:CHEMM · Home listing | Copenhagen | Denmark | DKK |
| gettex:CHY | gettex | Germany | EUR |
| LSIN:0DZ0 | LSIN | United Kingdom | DKK |
| Tradegate:CHY | Tradegate | Germany | EUR |
| LS Exchange:A0MS80 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A0MS80 | Lang & Schwarz | Germany | EUR |
| Frankfurt:CHY · This page | Frankfurt | Germany | EUR |
| Aquis:CHEMMC | Aquis | United Kingdom | DKK |
| Stuttgart:CHY | Stuttgart | Germany | EUR |
| OTC:CHHMF | OTC | United States | USD |
| Munich:CHY | Munich | Germany | EUR |
| Aquis:CHEMMC | Aquis | United Kingdom | DKK |
| Dusseldorf:CHY | Dusseldorf | Germany | EUR |
| Hamburg:CHY | Hamburg | Germany | EUR |
| Turquoise:CHEMMC | Turquoise | United Kingdom | DKK |
Valuation
P/E 58.0× against a median of 76.0×: 3rd lowest of 5 Diagnostics & research services companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 11.42B DKK
- P/E
- 58.0×
- EV/sales
- 22.3×
- EV/EBITDA
- 40.6×
- Price/book
- 16.1×
- Gross margin
- 95.1%
- Operating margin
- 49.1%
- Net margin
- 39.5%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| ChemoMetec A/S · OMXCOP:CHEMM | US$1.72B | US$1.68B | 58.0× | 22.3× | 40.6× | 16.1× | 39.5% | 0.0× | n/a |
| OneSource Specialty Pharma Limited · NSE:ONESOURCE | US$1.99B | US$2.18B | n/a | 12.0× | 50.9× | 3.1× | −0.1% | 0.3× | n/a |
| Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A · SSE:603456 | US$1.98B | US$1.78B | 22.0× | 2.2× | n/a | 1.5× | 11.3% | 0.0× | n/a |
| Azenta, Inc. · NASDAQ:AZTA | US$1.96B | US$1.63B | n/a | 2.6× | n/a | 1.4× | −26.9% | 0.0× | 1.59 |
| Syngene International Ltd. · NSE:SYNGENE | US$1.96B | US$1.96B | 97.5× | 5.2× | 20.0× | 3.7× | 5.3% | 0.1× | n/a |
| Cohance Lifesciences Ltd · NSE:COHANCE | US$1.91B | US$1.88B | 167× | 8.1× | 55.1× | 4.5× | 5.0% | 0.1× | n/a |
| Alamar Biosciences, Inc. · NASDAQ:ALMR | US$1.84B | US$1.66B | n/a | 14.5× | n/a | 6.1× | −48.2% | 0.1× | 1.70 |
| Fortrea Holdings Inc. · NASDAQ:FTRE | US$1.79B | US$2.62B | n/a | 1.0× | 28.7× | 3.4× | −2.6% | 2.0× | 1.68 |
| GemPharmatech Co., Ltd. Class A · SSE:688046 | US$1.65B | US$1.49B | 54.4× | 10.5× | n/a | 4.7× | 21.5% | 0.0× | n/a |
| PolyPeptide Group AG · SIX:PPGN | US$1.62B | US$1.70B | n/a | 4.0× | 34.1× | 4.2× | −5.4% | 0.4× | n/a |
| Personalis, Inc. · NASDAQ:PSNL | US$1.55B | US$1.39B | n/a | 17.3× | n/a | 7.3× | −147.7% | 0.2× | 2.03 |
| Median of the others | US$1.87B | US$1.74B | 76.0× | 6.7× | 34.1× | 4.0× | −1.3% | 0.1× | 1.69 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 780.00 DKK · Analysts' mean
- EPS, year to Jun 2027
- 14.64 · 3 analysts
- Revenue, year to Jun 2027
- 607M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Martin Helbo Behrens | CEO |
| Phillip Massie Price | CFO |
| Andrey Gorin | Laboratory Manager |
| Glenn Winnier | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Niels Thestrup | Chairman of the Board |
| Betina Hagerup | Member of the Board of Directors |
| Kristine Færch | Member of the Board of Directors |
| Martin Glensbjerg | Deputy Chairman |
| Peter Reich | Member of the Board of Directors |
Events
- Next results
- Feb 2, 2027 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2025 | May 7, 2025 | −5.4% |
| Q2 2025 | Feb 5, 2025 | +5.6% |
| Quarter to Sep 30, 2024 | Nov 7, 2024 | +29.8% |
| Q4 2024 | Sep 11, 2024 · After close | +0.2% |
| Q3 2024 | May 8, 2024 · Before open | −0.6% |
| Q2 2024 | Feb 5, 2024 · After close | +24.0% |
| Q1 2024 | Nov 7, 2023 · After close | +7.5% |
| Q4 2023 | Sep 13, 2023 · After close | −4.4% |
| Q3 2023 | May 9, 2023 | +4.1% |
| Q2 2023 | Feb 9, 2023 | −22.1% |
All 18 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2023 | Nov 8, 2022 · After close | +0.4% |
| Q4 2022 | Sep 15, 2022 · Before open | +0.2% |
| Q3 2022 | May 5, 2022 · Before open | +0.8% |
| Q2 2022 | Feb 8, 2022 · After close | +3.8% |
| Q1 2022 | Nov 4, 2021 · Before open | +0.4% |
| Q4 2021 | Sep 15, 2021 · After close | +3.0% |
| Q3 2021 | May 6, 2021 | −4.3% |
| Q2 2021 | Feb 5, 2021 · After close | +3.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| H1 2023/24 Earnings Presentation | Earnings | 14 slides | Feb 6, 2024 |
Financials
Annual, in DKK
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 511.1M | 495.6M | 407.4M | 444.4M | 428.4M | 281.1M | 214.1M | 175.5M | 112.7M | 90.3M |
| Cost of revenue | 25.1M | 30.1M | 40.3M | 49.0M | 44.1M | 27.8M | 20.2M | 16.9M | 13.2M | 10.1M |
| Gross profit | 486.0M | 465.5M | 367.6M | 395.4M | 384.3M | 253.3M | 193.9M | 158.6M | 99.5M | 80.2M |
| Research and development | 15.4M | 10.4M | 8.39M | 7.16M | 7.23M | 6.49M | 6.48M | 5.69M | 3.69M | 3.80M |
| Selling, general and administrative | 41.3M | 23.4M | 25.7M | 24.1M | 20.3M | 20.2M | ||||
| Operating income | 251.0M | 236.5M | 169.0M | 228.5M | 201.5M | 116.0M | 77.5M | 54.1M | 24.3M | 10.4M |
| Depreciation and amortization | 30.3M | 21.5M | 17.2M | 20.4M | 20.0M | 19.6M | 15.1M | 10.8M | 5.79M | 5.45M |
| EBITDA | 281.3M | 258.0M | 186.2M | 248.9M | 221.6M | 135.6M | 92.6M | 64.9M | 30.1M | 15.9M |
| Interest expense | 392.0K | 17.4M | 1.28M | 1.09M | 1.52M | 918.0K | 1.19M | 716.0K | 887.0K | 1.07M |
| Income before tax | 258.2M | 225.0M | 176.6M | 230.4M | 203.2M | 112.7M | 75.9M | 53.7M | 23.3M | 8.65M |
| Income tax | 56.3M | 50.3M | 40.3M | 51.7M | 43.8M | 24.4M | 16.8M | 11.9M | 5.09M | 1.17M |
| Net income | 201.8M | 174.7M | 136.3M | 178.7M | 159.5M | 88.4M | 59.2M | 41.8M | 18.2M | 7.49M |
| Earnings per share, basic | 11,600.00 | 10,040.00 | 7.83 | 10.27 | 9.16 | 5.08 | 3.51 | 2.69 | 1.17 | 0.48 |
| Earnings per share, diluted | 11,600.00 | 10,040.00 | 7.83 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 290.2M | 341.8M | 296.1M | 316.6M | 209.0M | 150.1M | 96.9M | 98.2M | 9.78M | 12.4M |
| Short-term investments | 3.39M | -93.8M | -82.6M | |||||||
| Receivables | 99.2M | 79.6M | 69.1M | 59.7M | 65.9M | 62.6M | 44.3M | 36.0M | 19.6M | 14.7M |
| Inventory | 126.2M | 120.8M | 119.5M | 112.6M | 66.8M | 30.1M | 25.1M | 19.5M | 16.8M | 13.3M |
| Current assets | 524.8M | 554.6M | 489.8M | 492.7M | 352.9M | 244.4M | 168.3M | 154.8M | 46.8M | 41.0M |
| Property, plant and equipment | 126.6M | 115.6M | 92.0M | 82.7M | 74.8M | 42.5M | 43.4M | 38.1M | 28.9M | 26.4M |
| Goodwill | 7.36M | 7.35M | 0 | |||||||
| Total assets | 860.9M | 839.5M | 676.7M | 658.0M | 501.3M | 344.9M | 263.1M | 238.2M | 114.0M | 97.6M |
| Accounts payable | 38.1M | 16.1M | 11.1M | 17.6M | 17.0M | 8.71M | 8.43M | 9.71M | 7.26M | 4.89M |
| Current liabilities | 128.2M | 143.7M | 98.5M | 119.2M | 137.4M | 72.0M | 47.7M | 55.0M | 17.9M | 21.1M |
| Long-term debt | 0 | 17.8M | 10.9M | |||||||
| Total debt | 4.59M | 6.40M | 4.16M | 7.16M | 6.79M | 2.36M | 2.29M | 18.8M | 20.1M | 22.1M |
| Total liabilities | 135.5M | 151.4M | 111.4M | 124.9M | 144.1M | 79.9M | 60.4M | 64.9M | 41.0M | 33.2M |
| Shareholders' equity | 725.4M | 688.1M | 565.3M | 533.0M | 357.2M | 265.0M | 202.8M | 173.3M | 73.0M | 64.4M |
| Shares outstanding | 17.4M | 17.4M | 17.4M | 17.4M | 17.4M | 17.4M | 16.9M | 15.6M | 15.5M | 15.7M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 210.4M | 207.4M | 129.0M | 154.1M | 176.9M | 107.9M | 72.0M | 58.3M | 25.4M | 9.76M |
| Capital spending | -28.3M | -29.9M | -20.9M | -40.8M | -55.9M | -24.6M | -26.7M | -27.1M | -16.5M | -10.6M |
| Free cash flow | 182.0M | 177.6M | 108.1M | 113.3M | 120.9M | 83.3M | 45.3M | 31.2M | 8.97M | -833.0K |
| Cash from investing | -99.8M | -85.5M | -43.5M | -40.8M | -56.0M | -24.7M | -26.6M | -27.1M | -16.5M | -10.3M |
| Cash from financing | -161.6M | -75.0M | -105.7M | -2.92M | -69.0M | -26.0M | -46.3M | 57.8M | -7.93M | -355.0K |
| Dividends paid | -121.8M | -69.6M | -104.4M | -69.6M | -26.1M | -348.1M | -136.0M | -136.0M | -136.0M | |
| Share buybacks | -38.6M | 1.87M | -9.57M | |||||||
| Change in cash | -51.0M | 47.0M | -20.2M | 107.5M | 58.9M | 53.2M | -1.25M | 89.0M | 933.0K | -1.70M |
Cap table
Built by 6ix from ChemoMetec A/S’ releases
- Common shares
- 17,162,529
- Fully diluted
- 17,162,529
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 17,162,529 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 17,162,529 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Betina Hagerup | Member of the Board of Directors · Since at least Mar 2, 2026 |
| Kristine Færch | Member of the Board of Directors · Since at least Oct 9, 2025 |
| Martin Glensbjerg | Deputy Chairman · Since at least Oct 9, 2025 |
| Martin Helbo Behrens | CEO · Since at least Sep 10, 2026 |
| Niels Thestrup | Chairman of the Board · Since at least Oct 9, 2025 |
| Peter Reich | Member of the Board of Directors · Since at least Oct 9, 2025 |
| Phillip Massie Price | CFO · Since at least Sep 10, 2026 |
Log in to ask 6ix AI your own questions about ChemoMetec A/S.